LOGIN  |  REGISTER
Amneal Pharmaceuticals

Latest Merger / Acquisition News

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

September 18
Last Trade: 145.71 0.84 0.58

Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ThecaFlex DRx™ has the potential to be a new, convenient way to administer medicines to patients living with neurological disorders. CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a...Read more


89bio Announces Agreement to be Acquired by Roche

September 18
Last Trade: 14.99 6.90 85.40

89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion  Transaction reflects pegozafermin’s potential best-in-disease profile for the treatment of moderate to severe metabolic...Read more


Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care

September 15
Last Trade: 11.86 0.00 0.00

ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas. Nexus is the maker of the proprietary TKO® anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including...Read more


Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak

September 12
Last Trade: 3.31 0.002 0.06

MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that its shareholders have approved the previously announced plan of arrangement (the “Arrangement”) under Chapter XVI – Division II of the Business Corporations Act (Québec) involving CB Biotechnology, LLC...Read more


MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

September 12
Last Trade: 1.27 -0.02 -1.55

SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL / ACCESS Newswire / September 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic...Read more


MBody AI and Check-Cap Enter into Definitive Merger Agreement

September 12
Last Trade: 2.21 -0.11 -4.78

Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI (“MBody AI”) and Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the “Merger”). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI...Read more


Bausch Health Completes Acquisition of DURECT, Expanding Late-stage Liver Disease Portfolio

September 11
Last Trade: 6.85 0.02 0.29

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, AND CUPERTINO, CA / ACCESS Newswire / September 11, 2025 / Bausch Health Companies Inc. (NYSE:BHC) (TSX:BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced the successful completion of its...Read more


GE HealthCare announces intent to acquire icometrix to strengthen neurology portfolio with brain MRI assessment solutions

September 10
Last Trade: 76.66 0.03 0.04

The anticipated acquisition aligns with GE HealthCare’s precision care strategy with the goal of strengthening the company’s portfolio of offerings in neurological care and its quantitative analysis of brain MRI icometrix’s icobrain platform – a comprehensive set of solutions for neurological disease analysis – includes icobrain aria, the first AI Computer-Aided Detection and Diagnosis FDA 510(k) cleared solution for detecting known side...Read more


Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

September 9
Last Trade: 47.75 0.05 0.10

Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion  Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases  Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing...Read more


NKGen Biotech Announces Completion of NKMax Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

September 9
Last Trade: 0.13 0.00 0.00

NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control. Approximately $16.9 million paid to acquire 65% equity stake in recapitalized debt-free NKMax, with NKMax operations now expected to be funded through 2026. Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y....Read more


Semnur Pharmaceuticals, a Majority-Owned Subsidiary of Scilex, and Denali Capital Acquisition Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination

September 4
Last Trade: 24.90 0.02 0.08

PALO ALTO, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the...Read more


Phreesia to Acquire AccessOne, Expanding Its Suite of Payment Solutions

September 4
Last Trade: 23.53 0.25 1.07

ALL-REMOTE COMPANY/WILMINGTON, Del. / Sep 04, 2025 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia”), a trusted leader in patient activation, today announced it has entered into a definitive agreement to acquire AccessOne Parent Holdings, Inc. (together with its subsidiaries, “AccessOne”), a portfolio company of Frontier Growth, for aggregate consideration of $160 million in cash (the “AccessOne Acquisition”). The transaction is...Read more


Quipt Home Medical Completes Strategic Acquisition of Hart Medical Adding $60 Million in Revenue

September 3
Last Trade: 2.64 -0.04 -1.49

Transaction Strengthens Health System Partnerships, Expands Midwest Footprint, and Reinforces Long-Term Growth Strategy CINCINNATI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the closing of its previously announced joint venture transaction with three major health...Read more


EUDA Health Signs Letter of Intent to Potentially Acquire Chemokine

August 28
Last Trade: 1.09 0.04 3.52

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations....Read more


Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices

August 27
Last Trade: 0.25 0.00 0.00

BETHESDA, Md., Aug. 27, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into an agreement to acquire Advent BioServices Ltd. from its owner, Toucan Holdings LLC. The transaction is expected to close as soon as certain legal conditions are fulfilled. At closing, Advent...Read more


MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

August 25
Last Trade: 5.49 0.10 1.86

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet need Upfront cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in cash Upfront cash...Read more


Forager Capital Management Submits Fully Financed Proposal to Acquire Quipt Home Medical for $3.10 Per Share in Cash

August 25
Last Trade: 2.64 -0.04 -1.49

Acquisition Proposal is Fully Financed and Requires No Further Diligence—Ready for Definitive Documents Prepared to Improve Offer Upon Constructive Engagement from Board BIRMINGHAM, Ala., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Forager Capital Management (“Forager”), one of the largest shareholders of Quipt Home Medical Corp. (“Quipt”) (NASDAQ: QIPT; TSX: QIPT), with beneficial ownership of 9.7%, today announced it has submitted a...Read more


Tempus AI Announces the Acquisition of Paige

August 22
Last Trade: 86.86 0.41 0.47

Paige’s strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated CHICAGO / Aug 22, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to...Read more


Gilead Sciences: Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

August 21
Last Trade: 112.13 -0.13 -0.12

SANTA MONICA, Calif. & PHILADELPHIA / Aug 21, 2025 / Business Wire / Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. This acquisition complements Kite's expertise in cell therapy by incorporating Interius's integrating in vivo platform. This approach...Read more


Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20
Last Trade: 2.08 0.00 0.00

WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty (“Sub”), has agreed to...Read more


AbbVie Completes Acquisition of Capstan Therapeutics

August 19
Last Trade: 220.48 -0.33 -0.15

Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform designed to deliver RNA payloads, such as mRNA, capable of engineering specific cell types in vivo NORTH CHICAGO, Ill., Aug. 19, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of...Read more


Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech, A Real-Time Fluid Monitoring Company

August 19
Last Trade: 3.87 -0.19 -4.68

Proposed acquisition supports strategy to drive technology expansion of fluid management offering to include continuous renal health monitoring technologies supporting the full patient journey, from early risk assessment to targeted fluid removal MINNEAPOLIS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on improving patient outcomes through advanced fluid management, today...Read more


Teladoc Health Acquires Telecare, Expanding Access to Specialist and Allied Health Care for Australians in Public and Private Health

August 14
Last Trade: 8.16 0.26 3.29

MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled provider of specialist and allied health care via virtual delivery. Telecare operates Australia's leading virtual care clinic and provides software solutions to the healthcare sector. With over 300 virtual specialists in over 30...Read more


Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

August 13
Last Trade: 2.39 0.00 0.00

Effective as of Commencement of Trading on August 15, 2025 CAMBRIDGE, Mass. / Aug 13, 2025 / Business Wire / Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company’s previously announced merger with ReShape Lifesciences...Read more


Cardinal Health announces the addition of Solaris Health, the country's leading urology MSO, to The Specialty Alliance

August 12
Last Trade: 148.94 0.26 0.17

Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty Alliance Joins with recent urology acquisitions to bolster The Specialty Alliance's leadership in the urology therapeutic area Cardinal Health MSO platforms reach ~3,000 providers in 32 states upon transaction close DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that The Specialty Alliance, its...Read more


Doximity Acquires Pathway, a Leader in AI Clinical Reference

August 7
Last Trade: 72.93 0.26 0.36

$63M acquisition brings physician AI team and datasets to Doximity’s AI suite SAN FRANCISCO / Aug 07, 2025 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway’s team. Over the past seven years,...Read more


10x Genomics to Acquire Scale Biosciences

August 7
Last Trade: 13.15 0.29 2.26

Acquisition Will Further Expand Chromium's Capabilities PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to acquire Scale Biosciences, Inc., a leader in innovative and scalable single cell analysis. The acquisition provides 10x with key inventions and technologies that will advance innovation...Read more


CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

August 7
Last Trade: 11.19 0.07 0.63

Transformational deal for CorMedix that expands and diversifies company’s commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million Pro forma 2025 combined revenues estimated to be $305 to $335...Read more


Alcon Agrees to Acquire STAAR Surgical

August 5
Last Trade: 77.17 -0.03 -0.04

STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon’s laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53...Read more


SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

August 5
Last Trade: 8.61 0.00 0.00

Acquisition to Include Naxitamab-gqgk DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio Transaction Expands SERB’s Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Share Price on August 4, 2025 WEST CONSHOHOCKEN, Pa. and PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- SERB...Read more


XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right

August 4
Last Trade: 38.45 1.71 4.65

XOMA Royalty adds milestone and royalty economics associated with two partnered assets EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today they have entered a definitive share purchase agreement (the “Purchase Agreement” and the transactions set forth in the...Read more


HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right

August 4
Last Trade: 2.09 0.00 0.00

BOSTON, Mass., and EMERYVILLE, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive merger agreement (the “Merger Agreement”), whereby XOMA Royalty will acquire all of the issued and outstanding common shares of HilleVax.   Under the terms of the Merger Agreement,...Read more


Bausch Health to Acquire DURECT, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

July 29
Last Trade: 6.85 0.02 0.29

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitis Proposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver disease complications globally LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / July 29, 2025 /...Read more


Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

July 29
Last Trade: 3.57 0.00 0.00

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Binding term sheet signed; transaction subject to customary conditions and approvals Closing expected in Q4 2025 GENEVA,...Read more


Eli Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

July 25
Last Trade: 770.00 9.87 1.30

INDIANAPOLIS, July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. "This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong...Read more


Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million

July 25
Last Trade: 17.16 0.00 0.00

The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the...Read more


Waystar to Acquire Iodine Software, Accelerating the AI-Powered Transformation of Healthcare Payments

July 23
Last Trade: 38.68 0.08 0.21

Extends Waystar's AI leadership into clinical intelligence software, unlocking greater value for clients and shareholders Highly recurring subscription-based business projected to be accretive to Waystar's financial profile Expected to expand Waystar's total addressable market by more than 15% Conference call to be held Wednesday, July 23, 2025, at 5:30 p.m. ET LEHI, Utah and LOUISVILLE, Ky., and AUSTIN, Texas, July 23, 2025...Read more


ZimVie Announces Definitive Agreement to be Acquired by ARCHIMED for $19.00 Per Share in Cash

July 21
Last Trade: 18.87 -0.01 -0.05

Transaction expected to close by year-end 2025 PALM BEACH GARDENS, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries. Under the terms of the...Read more


iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

July 21
Last Trade: 10.15 0.00 0.00

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share (“iTeos Common Stock”), plus one non-transferable contingent value right (“CVR”), which represents...Read more


RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD

July 17
Last Trade: 75.54 0.34 0.45

Acquisition contributes iCAD's commercial, technology, and regulatory capabilities The acquisition positions DeepHealth with an industry-leading suite of AI-powered breast cancer image interpretation and workflow solutions The combination is expected to provide acceleration of AI adoption and expanded worldwide access to advanced breast cancer screening and diagnosis technologies LOS ANGELES, July 17, 2025 (GLOBE...Read more


Aptorum Group and DiamiR Biosciences Enter into Definitive Merger Agreement

July 16
Last Trade: 1.82 0.02 1.06

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory...Read more


Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

July 16
Last Trade: 3.16 0.00 0.00

CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the “Merger Agreement”). Andrew J. Oakley, Chairman of the Board of Onconetix, stated,...Read more


Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

July 15
Last Trade: 17.16 0.00 0.00

Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena’s stockholders voted in favor of all proposals, including a proposal approving the...Read more


Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions

July 14
Last Trade: 99.76 -0.16 -0.16

Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to meet surgeons' needs  Acquisition expected to be neutral to adjusted earnings per share in 2025 – 2027 and accretive thereafter and to contribute to revenue growth beginning in 2027 WARSAW, Ind. and AUSTIN, Texas, July 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global...Read more


Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

July 14
Last Trade: 305.18 1.50 0.49

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over...Read more


ESSA Pharma Announces Definitive Agreement to be Acquired by XenoTherapeutics Backed by XOMA Royalty Corporation in All-Cash Transaction

July 14
Last Trade: 0.21 0.0053 2.61

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of...Read more


Longevity Health Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

July 14
Last Trade: 0.20 0.00 0.00

PITTSBURGH, July 14, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging (“Longevity”, the “Company”, “we”, “our”, or “us”), today announced the execution of a definitive merger agreement (the “Merger”) with True Health Inc., a leading player in the fast growing plasma collection industry under the THPlasma brand (“THPlasma”), to combine the companies in an...Read more


Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

July 9
Last Trade: 81.34 0.20 0.25

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Merck to hold investor call at 8 a.m. ET today RAHWAY, N.J. & RALEIGH, N.C. / Jul 09, 2025 / Business Wire / Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on...Read more


CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right

July 8
Last Trade: 4.47 0.00 0.00

SAN CARLOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO” or the “Company”) (NASDAQ: CRGX), a biotechnology company that has focused on developing CAR T-cell therapies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire CARGO for $4.379 in cash per share of CARGO common stock, par value...Read more


Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

July 7
Last Trade: 77.17 -0.03 -0.04

LumiThera’s photobiomodulation (PBM) device is the first and only technology that has demonstrated meaningful visual improvement with two years of treatments* in early and intermediate dry AMD patients1,2 Nearly 200 million people globally live with dry AMD, a progressive disease with no cure, and a leading cause of blindness in developed nations3,4 Alcon aims to expand PBM office-based treatment in approved markets, underscoring its...Read more


VitalHub Announces Acquisition of Novari Health

July 7
Last Trade: 11.46 0.44 3.99

TORONTO, July 07, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) is pleased to announce that it has acquired (the “Acquisition”) Novari Health Inc. (“Novari”), a leading healthcare software provider of patient flow solutions based in Canada. Transaction Details VitalHub has acquired Novari for total up-front consideration of $43.6 million, plus potential performance-based consideration. The...Read more


Quipt Home Medical Acquires Healthcare System Owned Medical Equipment Provider with $6.6 Million in Revenue, and Signs Preferred Provider Agreement Covering 20 Hospitals Across 4 States

July 7
Last Trade: 2.64 -0.04 -1.49

CINCINNATI, July 07, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced it has acquired a full-service durable medical equipment (“DME”) provider, which is wholly owned by Ballad Health (the “Acquiree”). Ballad Health is a prominent integrated health system comprised of 20 hospitals,...Read more


Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2
Last Trade: 3.31 0.002 0.06

Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share Upfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak’s initial non-binding proposal Transaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from...Read more


BioMarin Pharmaceutical Announces Completion of Acquisition of Inozyme

July 1
Last Trade: 54.57 0.20 0.37

SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently...Read more


Pennant Announces Home Health Acquisition in Southern California

July 1
Last Trade: 24.36 0.00 0.00

EAGLE, Idaho, July 01, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces the acquisition of a premier home health agency, GrandCare Health Services. The newly acquired agency, to be known as GrandCare Home Health, provides services in Los Angeles, Orange, Riverside and San Diego counties in...Read more


IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right

July 1
Last Trade: 1.27 0.00 0.00

MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common...Read more


AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology

June 30
Last Trade: 220.48 -0.33 -0.15

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo, and is a potential first-in-class product for treating B cell-mediated autoimmune diseases Proposed acquisition strengthens AbbVie's commitment to transforming the future of patient care with Capstan's innovative tLNP platform technology NORTH...Read more


Premier Expands Clinical Decision Support (CDS) Capabilities with Acquisition of IllumiCare

June 30
Last Trade: 26.53 -0.05 -0.19

IllumiCare’s cost attribution technology defines low-value care and makes costs transparent in real time, enabling improved financial performance. Compatible with 50-plus electronic medical record (EMR) systems, taps into a growing demand for solutions in outpatient and ambulatory settings. Unlocks potential growth opportunities across Premier’s service lines including clinical trial optimization, revenue cycle improvement and...Read more


Medicus Pharma Announces a Definitive Agreement to Acquire Antev UK

June 30
Last Trade: 5.69 0.00 0.00

Antev Shareholders to Receive Aggregate ~17% Equity Stake in Medicus plus US$65 Million in Contingent Payments Philadelphia, Pennsylvania--(Newsfile Corp. - June 30, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Antev Ltd. ("Antev"), a UK-based clinical-stage drug development company, announced today that they have entered into a definitive agreement dated June 29, 2025 (the "Definitive Agreement") pursuant to which...Read more


Turnstone Biologics Enters into Agreement to be Acquired by XOMA Royalty for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27
Last Trade: 38.45 1.71 4.65

EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a definitive merger agreement (“the Merger Agreement”), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock (“Turnstone common stock”) plus one...Read more


Enzo Biochem To be Acquired by Battery Ventures in All-Cash Transaction

June 24
Last Trade: 0.31 0.00 0.00

Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that on June 23, 2025, following the market close, it entered into an Agreement and Plan of Merger (the “Merger Agreement”) to be acquired by Battery Ventures, a global,...Read more


Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

June 23
Last Trade: 101.60 0.73 0.72

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools...Read more


Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

June 23
Last Trade: 1.42 0.10 7.88

Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform, focused on orthopedic diseases OrthoCellix is developing the Phase 3-ready NeoCart® as an autologous cartilage implant technology utilizing patient cells to repair articular cartilage defects of the knee PHILADELPHIA and MALVERN, Pa.,...Read more


TuHURA Biosciences and Kineta Stockholders Approve Proposed Merger and All Related Proposals

June 23
Last Trade: 0.34 0.00 0.00

TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT) ("Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune...Read more


VitalHub Completes Acquisition of Induction

June 19
Last Trade: 11.46 0.44 3.99

TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) announced that it has completed the cash acquisition of Induction Healthcare Group PLC (“Induction”) by way of a court-sanctioned scheme of arrangement (the “Acquisition”) under Part 26 of the Companies Act 2006. For full details related to the Acquisition, please see the circular related to the scheme of arrangement...Read more


Eli Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

June 17
Last Trade: 770.00 9.87 1.30

Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardiometabolic disease and genetic medicines are highly complementary to Verve's vision and expertise INDIANAPOLIS, June 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a...Read more


Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

June 16
Last Trade: 44.95 0.18 0.40

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform. Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis. Upfront cash payment...Read more


BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

June 12
Last Trade: 98.75 0.59 0.60

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing Public exchange offer for all shares of CureVac where each share...Read more


Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

June 9
Last Trade: 0.37 0.00 0.00

BOSTON, June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire...Read more


Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

June 5
Last Trade: 1.60 0.00 0.00

The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM, June 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I)...Read more


RadNet Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics

June 4
Last Trade: 75.54 0.34 0.45

See-Mode’s commercially available AI-powered ultrasound detection, characterization, and reporting solutions for thyroid and breast will be integrated into RadNet’s DeepHealth population health solutions Real-world deployment of See-Mode’s FDA-approved thyroid ultrasound solution at RadNet imaging centers demonstrates improved workflow efficiency and enhanced diagnostic accuracy The acquisition positions RadNet at the forefront of AI...Read more


Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

June 3
Last Trade: 32.59 0.48 1.49

Acquisition further expands Bruker’s multiomics strategy with biocrates metabolomics kits and assays, and related software and research services INNSBRUCK, Austria / Jun 03, 2025 / Business Wire / Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. biocrates is a global leader in mass spectrometry (MS)-based quantitative...Read more


Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

June 2
Last Trade: 129.46 0.00 0.00

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases, have entered into an agreement under which...Read more


atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

June 2
Last Trade: 4.77 0.16 3.47

Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic Combined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both...Read more


MDaudit and Streamline Health Solutions Announce Definitive Merger Agreement

May 29
Last Trade: 5.33 0.00 0.00

The combined entity supports healthcare organizations nationwide with an aggregate Net Patient Revenue of more than $300B and brings together best-in-class billing compliance and revenue integrity solutions to empower health systems with actionable foresight and end-to-end visibility. MDaudit to acquire all outstanding shares of Streamline stock for $5.34 per share in cash, a premium of 138% to Streamline’s closing price on May 28,...Read more


Eli Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

May 27
Last Trade: 770.00 9.87 1.30

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire...Read more


Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

May 21
Last Trade: 305.18 1.50 0.49

MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is...Read more


Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

May 21
Last Trade: 8.05 0.00 0.00

Vigil’s shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer’s...Read more


Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

May 21
Last Trade: 9.60 0.00 0.00

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek’s commercial portfolio...Read more


Merit Medical Systems Acquires Biolife Delaware

May 20
Last Trade: 82.93 0.23 0.28

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports. Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile Merit reaffirms full-year 2025 financial guidance previously...Read more


Regeneron Pharmaceuticals Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

May 19
Last Trade: 592.52 7.02 1.20

Purchase is subject to bankruptcy court and regulatory approvals Regeneron will prioritize the privacy, security and ethical use of 23andMe’s customer data; stands ready to work with independent, court-appointed Customer Privacy Ombudsman Planned purchase to strengthen Regeneron’s ongoing leadership in genetics-guided research and drug development to help people with serious diseases TARRYTOWN, N.Y., May 19, 2025 (GLOBE NEWSWIRE)...Read more


Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

May 19
Last Trade: 3.60 -0.08 -2.17

NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five...Read more


BioMarin Pharmaceutical Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 16
Last Trade: 54.57 0.20 0.37

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages  Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m....Read more


Alumis Stockholders Approve Merger with Acelyrin

May 13
Last Trade: 4.23 0.10 2.30

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC....Read more


Acelyrin Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 13
Last Trade: 2.27 0.00 0.00

LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced,...Read more


Castle Biosciences to Acquire Previse

May 5
Last Trade: 22.22 0.40 1.83

Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire...Read more


electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

May 2
Last Trade: 4.99 0.07 1.42

ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (Nasdaq: NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix’s Quell®...Read more


Resmed Acquires VirtuOx

May 1
Last Trade: 271.16 -0.55 -0.20

SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed’s commitment to improving the way care is delivered—by making it more accessible, more...Read more


Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

May 1
Last Trade: 0.88 0.00 0.00

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will...Read more


Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits

April 30
Last Trade: 8.16 0.26 3.29

PURCHASE, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired UpLift, an innovative and tech-enabled provider of virtual mental health therapy, psychiatry and medication management services.    The acquisition supports the company’s strategy to further enhance its leadership position in virtual mental health, including the ability for consumers served...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE